Ionis Pharmaceuticals IONS Revenue recognized that was included in deferred income at the beginning of the period

Revenue recognized that was included in deferred income at the beginning of the period at other companies

Antero ResourcesAR

$5.8M-7.0%

Ally FinancialALLY

$225M+5.1%

Ally FinancialALLY

$239M+0.4%

Hyatt HotelsH

$181M+7.7%

ModernaMRNA

$37M+363%

Baxter InternationalBAX

$182M+46.8%

Questions, answered.

What is Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period?

Ionis Pharmaceuticals (IONS) reported revenue recognized that was included in deferred income at the beginning of the period of $19.6M in Q4 2025.

How has Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period changed year-over-year?

Ionis Pharmaceuticals's revenue recognized that was included in deferred income at the beginning of the period decreased by 52.8% year-over-year, from $41.53M to $19.6M.

What does revenue recognized that was included in deferred income at the beginning of the period mean?

Revenue recognized this period that was previously recorded as a liability due to unfulfilled contract obligations.

How do you interpret revenue recognized that was included in deferred income at the beginning of the period?

An increase indicates successful execution of contract milestones and progress in drug development or licensing agreements.

How does revenue recognized that was included in deferred income at the beginning of the period compare across companies?

Standard for companies with long-term service or licensing contracts; peers in pharma often report this as milestone revenue.